A comparison of specificity and biological activity of polyclonal and monoclonal antibodies raised against R595 lipopolysaccharide Free

Abstract

Summary

Murine monoclonal antibodies (MAbs) and immune rabbit serum were raised against the rough mutant of strain R595. These antibodies were tested for their ability to inhibit LPS-induced B-cell mitogenicity and neutralise LPS toxicity in chick embryos. Immune rabbit serum inhibited both mitogenicity and LPS lethality. None of the MAbs or a cocktail of antibodies were able to neutralise LPS lethality in chick embryos. However, they were able to inhibit mitogenicity by varying degrees.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/00222615-31-2-85
1990-02-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/31/2/medmicro-31-2-85.html?itemId=/content/journal/jmm/10.1099/00222615-31-2-85&mimeType=html&fmt=ahah

References

  1. Appelmelk B J, Verweij-Van-Vught A M J J, Maclaren D M, Thiys L G. 1985; An enzyme-linked immunosorbent assay (ELISA) for the measurement of antibodies to different parts of the gram-negative lipopolysaccharide core region. Journal of Immunological Methods 82:199–207
    [Google Scholar]
  2. Appelmelk B J. 1988; Production and characterisation of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of gram-negative bacilli. Journal of Medical Microbiology 26:107–114
    [Google Scholar]
  3. Baumgartner J D et al. 1985; Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2:59–63
    [Google Scholar]
  4. Bogard W C, Abernethy K, Dunn D L, Kung P C. 1984; Murine monoclonal antibodies against gram-negative bacterial core-glycolipid : criteria for cross-genera reactivity. Federation Proceedings 43:1682 abstract no. 1553.
    [Google Scholar]
  5. Braude A I, Ziegler E J, Douglas H, McCutchan J A. 1977; Antibody to cell wall glycolipid of gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. Journal of Infectious Diseases 136:S167–S173
    [Google Scholar]
  6. Crowley J P, Zinner S H, Peter G. 1982; Opsonization of serumsensitive and serum-resistant Escherichia coli by rough mutant (Re) antisera. Journal of Laboratory and Clinical Medicine 99:197–205
    [Google Scholar]
  7. Dunn D L, Mach P A, Cerra F B. 1983; Monoclonal antibodies protect against lethal effects of gram-negative bacterial sepsis. Surgical Forum 44:142–143
    [Google Scholar]
  8. Dunn D L, Bogard W C, Cerra F B. 1985; Enhanced survival during murine gram-negative bacterial sepsis by use of a murine monoclonal antibody. Archives of Surgery 120:50–53
    [Google Scholar]
  9. Dunn D L, Ewald D C, Chandan N, Cerra F B. 1986; Immunotherapy of gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection. Archives of Surgery 121:58–62
    [Google Scholar]
  10. Eisenstein T K. 1975; Evidence of O-antigens as the antigenic determinants in “ribosomal” vaccines prepared from Salmonella. Infection and Immunity 12:364–377
    [Google Scholar]
  11. Galanos C, Luderitz O, Westphal O. 1969; A new method for the extraction of R-lipopolysaccharides. European Journal of Biochemistry 9:245–249
    [Google Scholar]
  12. Galanos C, Luderitz O, Westphal O. 1971; Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. European Journal Biochemistry 24:116–122
    [Google Scholar]
  13. Galanos C, Freudenberg M, Hase S, Jay F, Ruschmann E. 1977; Biological activitiesimmunological properties of lipid. Schlessinger D A. Microbiology American Society of Microbiology Washington, DC:269–276
    [Google Scholar]
  14. Galfre G, Milstein- C. 1982; Chemical typing of human kappa light chain subgroups expressed by human hybrid myelomas. Immunology 45:125–128
    [Google Scholar]
  15. Greisman S E, Dubuy J B, Woodward C L. 1978; Experimental gram-negative bacterial sepsis : re-evaluation of the ability of rough mutant antisera to protect mice. Proceedings of the Society for Experimental Biology and Medicine 158:482–490
    [Google Scholar]
  16. Ivanyi J, Davies P. 1980; Monoclonal antibodies against human growth hormone. Molecular Immunology 17:287–290
    [Google Scholar]
  17. Johns M, Skehill A, McCabe W R. 1983; Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to 0 and rough antigens against endotoxin. Journal of Infectious Diseases 147:57–67
    [Google Scholar]
  18. Kohler G, Milstein C. 1976; Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
    [Google Scholar]
  19. Kreger B E, Craven D E, Carling P C, McCabe W R. 1980; Gram-negative bacteremia. 111. Reassessment of etiology, epidemiology and ecology in 61 2 patients. American Journal of Medicine 68:332–343
    [Google Scholar]
  20. McCabe W R. 1972; Immunization with R mutants of S minnesota. I. Protection against challenge with heterologous gram-negative bacilli. Journalof Immunology 108:601–610
    [Google Scholar]
  21. Mehta N D, Wilson B M, Rapson N T, Easmon C S F. 1988; Comparison of the opsonic activity of polyclonal and monoclonal antibodies raised against Salmonella minnesota R595. Journal of Medical Microbiology 25:85–93
    [Google Scholar]
  22. Milner K C, Finkelstein R A. 1966; Bioassay of endotoxin: correlation between pyrogenicity for rabbits and lethality for chick embryos. Journal of Infectious Diseases 116:529–536
    [Google Scholar]
  23. Morrison D C, Ulevitch R J. 1978; The effects of bacterial endotoxins on host mediation systems. A review. American Journal of Pathology 93:526–617
    [Google Scholar]
  24. Ng A K, Chen C L H, Chang C M, Nowotny A. 1976; Relationship of structure to function in bacterial endotoxins : serologically cross-reactive components and their effect on protection of mice against some gram-negative infections. Journalof General Microbiology 94:107–116
    [Google Scholar]
  25. Pennington J E, Menkes E. 1981; Type-specific vs. crossprotective vaccination for gram-negative bacterial pneumonia. Journal of Infectious Diseases 144:599–603
    [Google Scholar]
  26. Pollack M, Raubitschek A A, Larrick J W. 1987; Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. Journal of Clinical Investigation 79:1421–1430
    [Google Scholar]
  27. Ramachandra R N, Berczi I, Sehon A H. 1988; Human-human hybridomas secreting lipid A monoclonal antibodies. Immunology Letters 18:93–98
    [Google Scholar]
  28. Raubitschek A A, Pollack M, Larrick J W. 1985; Preparation of human monoclonal antibodies (mAbs) that react with the conserved core region of endotoxin (LPS). Clinical Research 33:416A
    [Google Scholar]
  29. Rietschel E T, Sidorczyk L, Zahringer U, Wollenweber H-W, Luderitz O. 1983; Analysis of the primary structure of lipid A. Anderson L, Unger F M. Bacterial lipopolysaccharides. Structure, synthesis, biological activities American Chemical Symposium Series 231 American Chemical Society; Washington, DC:195–218
    [Google Scholar]
  30. Svenson S B, Nurminen M, Lindberg A A. 1979 Artificial salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infection and Immunity 25:863–872
    [Google Scholar]
  31. Taylor R L, Conrad H E. 1972; Stoichiometric depolymerization of polyuronides and glucosaminoglycuronans to monosaccharides following reduction to their carbodiimide-activated carboxyl groups. Biochemistry 11:1383–1388
    [Google Scholar]
  32. Telzak E E, Wolff S M. 1985; Immunotherapy and immunoprophylaxis of gram-negative rod bacteremia. Root R K, Sande M A. Septic shock Churchill Livingstone; New York:257–276
    [Google Scholar]
  33. Teng N N H et al. 1985; Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proceedings of the National Academy of Sciences of the USA 82:1790–1794
    [Google Scholar]
  34. Van Dijk W C, Verbrugh H A, Van Erne-Van Der To1 M E, Peters R, Verhoef J. 1981; Escherichia coli antibodies in opsonisation and protection against infection. Journal of Medical Microbiology 14:381–389
    [Google Scholar]
  35. Westphal O, Jann K. 1965; Bacterial lipopolysaccharides. Extraction with phenol water and further applications of the procedure. Methods in carbohydrate chemistry 5:83–91
    [Google Scholar]
  36. Wolff S M. 1982; The treatment of gram-negative bacteremia and shock (editorial). New England Journal of Medicine 307:1267–1268
    [Google Scholar]
  37. Ziegler E J, Douglas H, Sherman J E, Davis C E, Braude A I. 1973; Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-Gal epimerase-deficient mutant. Journal of Immunology 111:433–438
    [Google Scholar]
  38. Ziegler E J et al. 1982; Treatment of gram-negative bacteraemia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medicine 307:1225–1230
    [Google Scholar]
  39. Zinner S H, Peter G. 1983; The potential role of cell wall core glycolipids in the immunoprophylaxis and therapy of gramnegative rod bacteraemia. Easmon C S F, Jeljaszewicz J. Medical microbiology 11: Academic Press; London:71–851267–1268
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/00222615-31-2-85
Loading
/content/journal/jmm/10.1099/00222615-31-2-85
Loading

Data & Media loading...

Most cited Most Cited RSS feed